NCT01202266 - A Multiple Dose Study Of PF-05161704 In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast

DRUG

PF-05161704 or Placebo

PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven